ClinicalTrials.gg

Program

Amphetamine

Also written as “ADZENYS XR-ODT”, “Amphetamine Sulfate” and “Amphetamine Extended Release (ER) Tablet 20 mg”.

Its studies are mostly in Attention Deficit Disorder with Hyperactivity, led by 3 companies.

Furthest: phase 4, since Jul 23, 20186 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tris Pharma30 open or runningphase 4since Jul 23, 2018Mar 9, 2017none ahead
Azurity Pharmaceuticals20 open or runningphase 4since Nov 11, 2013Nov 11, 2013none ahead
Aytu BioPharma10 open or runningphase 4since Sep 5, 2025Sep 5, 2025none ahead

Also a collaborator on its studies: Takeda.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 11, 2013First study: phase 4 study in Attention Deficit Disorder with HyperactivityNew to Azurity PharmaceuticalsAzurity Pharmaceuticals · NCT01986062 · 97 enrolled · United States
  2. Mar 9, 2017Tris Pharma's first study: phase 3 study in Attention Deficit Disorder with HyperactivityNew to Tris PharmaTris Pharma · NCT03088267 · 18 enrolled · United States
  3. Jul 23, 2018Phase 4 study in Attention Deficit Disorder with HyperactivityTris Pharma · NCT03610464 · 5 enrolled · United States
  4. Aug 29, 2018Phase 3 study in Attention Deficit Disorder with HyperactivityAzurity Pharmaceuticals · NCT03659929 · 320 enrolled · United States
  5. Jul 16, 2019Phase 2 study in Attention Deficit Disorder with HyperactivityTris Pharma · NCT04027361 · 41 enrolled · United States
  6. Sep 5, 2025Aytu BioPharma's first study: phase 4 study in Attention Deficit Disorder with HyperactivityNew to Aytu BioPharmaAytu BioPharma · NCT07169162 · United States

TargetBeta

“Dopamine transporter releasing agent; Dopamine transporter releasing agent; Dopamine transporter releasing agent; Dopamine transporter releasing agent”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
lisdexamfetamineruleTakedaphase 447
BupropionruleGlaxoSmithKlinephase 429
dexmethylphenidaterulecingulate-therapeuticsphase 414

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07169162Attention Deficit Disorder with Hyperactivity · United States4WithdrawnAytu BioPharmaSep 5, 20250
NCT04027361Attention Deficit Disorder with Hyperactivity · United States2CompletedTris PharmaOct 15, 202141
NCT03659929Attention Deficit Disorder with Hyperactivity · United States3CompletedAzurity PharmaceuticalsApr 12, 2019320
NCT03610464Attention Deficit Disorder with Hyperactivity · United States4CompletedTris PharmaMay 23, 20185
NCT03088267Attention Deficit Disorder with Hyperactivity · United States3CompletedTris PharmaFeb 25, 201718
NCT01986062Attention Deficit Disorder with Hyperactivity · United States4CompletedAzurity PharmaceuticalsMay 201497

How it is read

Names in the registry

  • “ADZENYS XR-ODT”, 1 entry
  • “Amphetamine Sulfate”, 1 entry
  • “Amphetamine Extended Release (ER) Tablet 20 mg”, 1 entry
  • “Amphetamine + SPD503”, 1 entry
  • “Amphetamine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.